Med BioGene Inc. today announced that 2,318,000 warrants and agents' warrants to purchase an equal number of common shares of MBI at a price of $0.10 per share were exercised for gross proceeds to MBI of $231,800. As such, MBI currently has cash and cash equivalents of approximately $470,000.

Cynapsus Therapeutics Inc. developing the only non-injectable delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the three months ended March 31, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

BIOLASE, Inc. the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration has cleared the NewTom™ BIOLASE VG3 digital panoramic, cephalometric, and tomographic extra-oral X-ray system which BIOLASE® will market and distribute in the U.S.

Naturally Splendid Enterprises Ltd. (TSX VENTURE:NSP) (Naturally Splendid) is pleased to announce it has entered into a Sales Agreement with Canadian Medical Hemp Inc. (CMH) to market and distribute in Canada HempOmega™, on an exclusive basis, and H2Omega™, on a non-exclusive basis. Naturally Splendid will also have the right to market and distribute HempOmega™ and H2Omega™ in the United States on a non-exclusive basis.

BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, announced today that the U.S. Patent and Trademark Office ("USPTO") has awarded BIOLASE® two new patents.